Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
377
datasets available to search
ShareScore release 0.9.0
Dataset results
377 results for “GLP-1”
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
ClinicalTrials.gov study NCT00763451. IPD Sharing: Not stated. Countries: 15. Publications: 3.
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
ClinicalTrials.gov study NCT03767543. IPD Sharing: YES. Countries: 1. Publications: 2.
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
ClinicalTrials.gov study NCT00905255. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of Glutamine on GLP-1 and Insulin Secretion in Man
ClinicalTrials.gov study NCT00673894. IPD Sharing: NO. Countries: 1. Publications: 3.
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
ClinicalTrials.gov study NCT05313529. IPD Sharing: YES. Countries: 1. Publications: 4.
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
ClinicalTrials.gov study NCT04466618. IPD Sharing: NO. Countries: 1. Publications: 1.
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
ClinicalTrials.gov study NCT03232112. IPD Sharing: YES. Countries: 1. Publications: 1.
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
ClinicalTrials.gov study NCT03151005. IPD Sharing: YES. Countries: 1. Publications: 12.
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT02227849. IPD Sharing: Not stated. Countries: 1. Publications: 1.
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
ClinicalTrials.gov study NCT01524705. IPD Sharing: YES. Countries: 1. Publications: 46.
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
ClinicalTrials.gov study NCT01676116. IPD Sharing: Not stated. Countries: 5. Publications: 3.
An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking
Open the record for dataset details and reuse information.
GLP-1 Increases pre-ingestive satiation via hypothalamic circuits in mice and humans
Open the record for dataset details and reuse information.
Engineered probiotic restores glp-1 signaling to ameliorate fiber-deficiency-exacerbated colitis
Open the record for dataset details and reuse information.
Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes
<p><span><b>Context:</b> Novel dual GIP and GLP-1 receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide.</span></p> <p><span><b>Objective:</b> Explore mechanisms of glucose control by tirzepatide. </span></p> <p><span><b>Design:</b> <i>Post-hoc</i> analyses of fasting biomarkers and multiple linear regression analysis.</span></p> <p><span><b>Setting:</b> 47 sites in 4 countries.</span></p> <p><span><b>Patients or Other Participants:</b> 316 subjects with Type 2 diabetes.</span></p> <p><span><b>Interventions:</b> Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), placebo. </span></p> <p><span><b>Main Outcome Measures:</b> Analyze biomarkers of beta-cell function and insulin resistance (IR) and evaluate WL contributions to IR improvements at 26 weeks. </span></p> <p><span><b>Results:</b> HOMA2-B significantly increased with dulaglutide and tirzepatide 5, 10, and 15 mg compared with placebo (p<u><</u>0.02). Proinsulin/insulin and proinsulin/C-peptide ratios significantly decreased with tirzepatide 10 and 15 mg compared with placebo and dulaglutide (p<u><</u>0.007). Tirzepatide 10 and 15 mg significantly decreased fasting insulin (p<u><</u>0.033) and tirzepatide 10 mg significantly decreased HOMA2-IR (p=0.004) compared with placebo and dulaglutide. Markers of improved insulin sensitivity (IS) adiponectin, IGFBP-1, and IGFBP-2 significantly increased by one or more doses of tirzepatide (p<0.05). To determine whether improvements in IR were directly attributable to WL, multiple linear regression analysis with potential confounding variables age, sex, metformin, triglycerides, and HbA1c was conducted. WL significantly (p<u><</u>0.028) explained only 13% and 21% of improvement in HOMA2-IR with tirzepatide 10 and 15 mg, respectively. </span></p> <p><span><b>Conclusions:</b> Tirzepatide improved markers of IS and beta-cell function to a greater extent than dulaglutide. IS effects of tirzepatide were only partly attributable to WL, suggesting dual receptor agonism confers distinct mechanisms of glycemic control.</span></p>
Fig. 4. GLP-1 in Cucurbitane-type triterpenoids from the vines of Momordica charantia and their anti-inflammatory, cytotoxic, and antidiabetic activity
Fig. 4. GLP-1 secretory effects of compounds 1, 3, and 7 in STC-1 cells. GLP-1 secretory response under each condition was illustrated. Rutin (25 μg/mL) is positive control. Data represent Means ± SEM (n = 4). ***P <0.001, compared with None.
Fig. 6 in Norlignans as potent GLP-1 secretagogues from the fruits of Amomum villosum
Fig. 6. The stimulation of fractions and compounds on GLP-1 secretion. Oleoylethanolamide (OEA) was used as positive control. Data were expressed as mean ± SD (n = 3). **p <0.01, ***p <0.001.
Fig. 5 in Norlignans as potent GLP-1 secretagogues from the fruits of Amomum villosum
Fig. 5. Antidiabetic effects of A. villosum on db/db mice, (A–E) random blood glucose (0–4 weeks), (F) fasting blood glucose (4th week), (G) plasma insulin level, (H) plasma leptin level, (I) OGTT, (J) ITT, (K) food intake, and (L) body weight. Data were presented as mean ±SDs (n =8). *p <0.05, **p <0.01 vs Vehicle, ##p <0.01, ###p <0.001, ####p <0.0001 vs Lean.
GIP and GLP-1 in Type 1 Diabetes
ClinicalTrials.gov study NCT01739283. IPD Sharing: Not stated. Countries: 1. Publications: 1.
GLP-1 REceptor Agonists and Real World EvIdeNce
ClinicalTrials.gov study NCT03959865. IPD Sharing: NO. Countries: 1. Publications: 6.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.